FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancer.
We have recently shown that the immunophilin FKBP5 (also known as FKBP51) is a scaffolding protein that can enhance PHLPP-AKT interaction and facilitate PHLPP-mediated dephosphorylation of Akt Ser473, negatively regulating Akt activation in vitro. Therefore, FKBP5 might function as a tumor suppresso...
Main Authors: | Junmei Hou, Liewei Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3348935?pdf=render |
Similar Items
-
Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma.
by: Katarzyna A Ellsworth, et al.
Published: (2013-01-01) -
Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer
by: Daniela Massihnia, et al.
Published: (2017-01-01) -
Role of ABCC5 in Gemcitabine Resistance in Pancreatic Cancer
by: Bugde, Piyush
Published: (2019) -
Pancreatic Cancer Chemoresistance to Gemcitabine
by: Manoj Amrutkar, et al.
Published: (2017-11-01) -
PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer
by: Wenbin Li, et al.
Published: (2020-03-01)